: :
Fig 6 A, ultrasound, andB, radioisotope scan on apatient who had a large mass involving the left lobe ofthe thyroid. The ultrasonogram shows that the cold area on the isotope scan returns low level echoes characteristic ofmalignancy
Conclusion
These preliminary results show that the technique of displaying low level echoes from normal glandular tissue adds considerably to the differential diagnosis of thyroid swellings. Whereas the radioisotope scan provides valuable data on the functional status of the thyroid gland, cold areas can be due to glandular tissue, malignancy, or cystic change. Ultrasonic examination provides valuable complementary data by visualizing the anatomy and pathological structure of the involved area. 
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Measurement ofIntrathyroidal Iodine by Neutron Activation Analysis
The value of the measurement of exchangeable iodine in the thyroid gland is widely accepted and the technique of its measurement (Nodine et al. 1957 ) is well known. The clinical value of the measurement of total intrathyroidal iodine is potentially considerable, and this report outlines a method which has been developed for its measurement.
The technique, based on in vivo neutron activation analysis, employs a suitable beam of neutrons for the irradiation of the front section of the neck. The iodine-128 radioactivity induced in the thyroid gland is subsequently measured using a high sensitivity external monitor. Comparison of the counting rate with that from mock thyroid glands, contained in appropriate neck phantoms and treated identically, provides a measurement of the total iodine content of the thyroid.
In developing a technique of in vivo activation analysis there are several important factors which require detailed consideration and evaluation:
(1) Activation: With the range of biological variations encountered, comparison with phantoms is justified only if there is an acceptable level of uniformity of activation. In the case of sequential studies, however, it is sufficient to ensure that reproducibility of the activation parameters is maintained between successive measurements. Also, the incident neutron spectrum should be selected to minimize, where possible, the production of interfering isotopes.
(2) Monitoring: High sensitivity monitoring equipment is necessary to detect the very low levels (generally nanocuries) of induced activity. It is evident that detector size governs the overall sensitivityper unit dose and also the uniformity attainable for detection, which must satisfactorily accommodate the expected biological variations. In sequential studies, again, reproducibility between successive measurements will suffice.
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(3) Radiation dose: The radiation dose not only to the principal organ of interest but also to the surrounding tissue must be minimized; and its acceptability can be assessed by comparison with comparable diagnostic tests.
(4) Patient amenity: This is an important aspect both generally and also since it could influence the reproducibility.
Method
When these studies began the most suitable source of neutrons available was the UTR-300 reactor. Preliminary studies, reported previously (Boddy 1966) , showed that satisfactory results were obtainable using a collimated beam of neutrons from the horizontal beam tube of the reactor. It was shown later (Boddy & Alexander 1967 , Boddy et al. 1968 ) that use of the neutron beam emerging from the central vertical stringer (CVS) of the reactor resulted in improved uniformity of activation in the thyroid region of the neck.
Neutron flux and spectra measurements showed that the beam from the CVS contained a higher proportion of epithermal and fast neutrons than in the beam emerging from the horizontal beam tube. It was found, for both the horizontal and vertical beams, that the iodine-activation decreased almost linearly with depth in a neck phantom. However, improved uniformity of activation was achieved when the thermal neutron component of the incident CVS beam was absorbed using a boron filter: the activation fluence being provided by the moderation, within the neck, of the epithermal and fast neutrons. In addition, use of the filtered beam preferentially reduced the formation of the two principal interfering isotopes, namely '4Na and 3821; the reduction factors for these interfering isotopes and 12I being approximately 10 and 2 respectively.
Measurement of the induced 1281 was carried out in a high sensitivity monitor which has been developed for partial body in vivo activation analysis. This monitor conists of two sodiumiodide detectors, 7.6 cm diameter x 7.6 cm thick, mounted in two 10.2 cm thick lead collimators. A description of the monitor together with quantitative evaluation of the activation and detection characteristics has been reported (Boddy et al. 1970) . It was shown that use of the filtered CVS beam provided acceptable uniformity (maximum variation of 7%) for all gland sizes up to a mean depth of 3.0 cm. Similarly, the detection uniformity showed that a maximum variation of 8 % was encountered only for small glands situated at the front and deep in the neck.
Confirmation that these estimates were realistic was obtained by examining phantoms containing mock glands of volumes ranging from 10 to 175 ml. The maximum combined variation was 14% which was in excellent agreement with that predicted from the activation and detection characteristics.
Extensive studies on sensitivity and spectrum analysis have indicated that use of a whole body monitor (Boddy 1967 ) employing a large sodium iodide detector (29.2 cm diameter x 10.2 cm thick) gives greater sensitivity and improved accuracy for the correction for interfering isotopes. Since the detection uniformity is at least as good as that of the partial body monitor the whole body monitor is now used for these thyroid studies.
Detailed dosimetry studies have been carried out for both the filtered and unfiltered beams. It has been shown (Boddy et al. 1969) in the case of the filtered beam that a 5-minute exposure at 20 kW reactor power delivers a neutron dose of approximately 20 rem. The concurrent gamma dose is 2 rem. This level of radiation dose seems acceptable since it is comparable with or less than the doses received in standard radioiodine tests.
With these activation parameters and a 15 minute monitoring period, the counting error for a gland containing 10 mg I is approximately 2%. The sensitivity or minimum detectable amount is 0.3 mgI.
Measurements on mock thyroids have been shown to be in good agreement with the results of chemical analyses. Similar intercomparison studies have also been carried out on post-mortem thyroids and a limited number of patients have now been examined using the method. The results of these recent measurements are currently being evaluated and prepared for publication.
While it has been shown that the UTR-300 reactor is suitable for these studies, in general, the availability of a reactor for clinical studies is limited. In the last few years californium-252, which decays by spontaneous fission with a halflife of 2.65 years, has become available commercially. The inherent similarity between the neutron spectrum of the reactor and that of californium-252 made the future use of this isotope an attractive proposition for in vivo studies.
Recently the department acquired two californium-252 sources for use in partial body in vivo activation analysis. Each source of 200 ,ug 252Cf, emitting approximately 4 x 108 neutrons/sec, is encapsulated in a small cylindrical steel container, 1.0 cm x 0.7 cm diameter. A pneumatic system is used to transfer each source independently from the storage location to the desired irradiation position.
The conditions for activation have been investigated by examining the influence of premoderators, reflectors and air gaps on the uniformity of activation and on the sensitivity for the measurement of iodine. These investigations together with dose measurements show (Boddy et al. 1974 ) that irradiation and monitoring periods each of 20 minutes are necessary to obtain a sufficient level of sensitivity per unit dose. Depending on the actual compromise chosen between sensitivity and activation uniformity, the error for the measurement of 10 mg of iodine ranged from 8.3% to 3.4% while the total radiation dose ranged from 10 to 23 rem. The corresponding values for the minimum detectable amount were 1.7 and 0.6 mg I.
While it appears that the reactor spectrum is more suitable for the activation of iodine in the thyroid, nevertheless californium-252 could be used satisfactorily in a technique for the measurement of intrathyroidal iodine. This report has dealt only with the measurement of iodine in the thyroid gland; however, it has been shown (Boddy et al. 1974 ) that californium-252 can be used effectively in the measurement of other body elements, principally the measurement of calcium in sections of the limbs. Obviously californium-252 has considerable potential importance in partial body in vivo activation analysis: much of this importance must be related to the ease with which californium sources could be installed and used in the clinical environment. The recent introduction of the 99Tcm-labelled phosphate compounds has made high quality bone scans available in all hospitals with scanning facilities (Citrin, Bessent & Tuohy 1974) . Bone scanning may be particularly useful in the study of breast cancer because of the high incidence of bone metastases in this condition (Jaffe 1958), and the ability of the scan to identify metastases while radiographs are still normal (Charkes et al. 1968 ). Using 15 mCi of 99Tcm-EHDP, which appears to be the most favourable of the 99Tcmphosphates (Citrin et al. 1975 ), a gamma camera axial skeleton scan (Galasko et al. 1968 ) is completed within 30-45 minutes. After the initial intravenous administration of radiopharmaceutical the procedure is entirely non-invasive. Outpatient studies are easily performed.
We have scanned 178 patients with breast cancer and our results confirm a higher incidence of metastases observed with the scan than with conventional radiography: all but two of 47 patients with known X-ray positive lesions were also scan positive and in 24 (50 %) the scan showed more widespread disease than the radiograph. In 60 patients where metastases were clinically suspected but radiographs showed no definite abnormality, the scan was positive in 29 (49%). Follow up of these patients has been undertaken and we have confirmed the presence of metastases at the sites initially indicated by the scan in several patients.
To date 71 patients with primary breast cancer have been studied with 99Tcm-EHDP. Bone scans were performed as part of the initial assessment before surgical treatment of the primary disease; 23 (33%) have definite scan evidence of skeletal metastases. In no patient did a conventional radiographic skeletal survey, reported by an experienced consultant radiologist, show evidence of metastatic disease. Clinical staging of the 23 patients is shown in Table 1 . It is clear that bone scanning can provide evidence of dissemination in many patients with apparently early breast cancer.
A prospective study of patients with primary breast cancer is in progress at Glasgow Royal
